| Biological Information | |
|---|---|
| Background Information: | c-Kit (V654A) is an acquired resistance mutation which has been found in patients with gastrointestinal stromal tumors (GISTs) undergoing treatment with Imatinib. The V654A mutation is strongly correlated with Imatinib resistance and rapid progression of GISTs. (Chen LL et al., Cancer Research, (2004); 64:5913-5919). |
| Target Class: | Kinase |
| Family: | Receptor Tyrosine Kinase |
| Accession Number: | NM_000222.2; NM_001093772.1 |
| Target Name: | c-Kit |
| Target Aliases: | KIT, C-Kit, PBT, CD117, SCFR, c-kit |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 6 months at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
c-Kit (V654A), active
10 µg of active c-Kit. N-terminal GST-tagged recombinant, human c-Kit amino acids 544 – end containing the V654A mutation.
Datasheets
14-733x Datasheet
View Document